Emergex Vaccine Holding Limited
NIAID will conduct and sponsor clinical trials to accelerate and streamline the rapid development of next-generation COVID-19 vaccines.
ABINGDON, United Kingdom, October 2, 2024 (GLOBE NEWSWIRE) — Emergex Vaccine Holding Limited (“Emergex” or the “Company”) is a clinical company that aims to address the world’s major infectious diseases through the development of synthetic T cells. is a biotechnology company. Priming Vaccine Candidates today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (Bethesda, Maryland, USA), has selected Emergex for Project NextGen. Through Project NextGen, NIAID is conducting early-stage clinical trials on selected next-generation SARS-CoV-2 vaccine candidates across a wide range of platforms, including T-cell vaccines. The purpose of Emergex’s T cell-based platform is to generate a protective cellular immune response, specifically the generation of tissue-resident memory CD8 + T cells, which, in the case of SARS-CoV-2, can be used to rapidly recall locally. can provide a response. Respiratory tract causing miscarriage infection. The induction of mutation-independent and long-lasting cell-mediated protection limits the need for frequent boosters. The Emergex vaccine, CoronaTcP, is designed to be broadly effective against betacoronavirus infections, including SARS-CoV-1 as well as known and emerging variants of SARS-CoV-2.
Professor Thomas Rademacher, co-founder and chief executive officer of Emergex, said: Selected as part of the Project NextGen initiative. Our T-cell-based platform technology harnesses the natural processes of cellular immunity by ensuring rapid, targeted, and strong immune responses against emerging infectious threats to help combat current and future coronavirus infections. It has the potential to address the challenges of the virus and thereby strengthen our preparedness for future pandemics. ”
Emergex’s CoronaTcP candidate has a favorable safety profile in a Phase I clinical trial completed in Switzerland and is an epitope-specific candidate important for long-term protection against betacoronaviruses in the face of high mutation rates and continued mutation. We demonstrated successful induction of CD8+ memory subset. The emergence of new variants of those viruses. The company is also employing a variety of microneedle devices to enable transdermal delivery of 100% synthetic vaccines and promote the development of both systemic and tissue-endogenous CD8 T-cell memory responses. Additionally, this delivery approach can overcome the logistical constraints of traditional vaccines, which require cold-chain measures during transportation, manufacturing, and traditional administration by healthcare workers, all of which are important to the global Access may be severely restricted.
story continues
Emergex is looking forward to this important next step in the development of a novel T-cell priming betacoronavirus candidate. NIAID is expected to fully cover the cost of the Phase I clinical trial, including surgery and related analyses. Emergex is responsible for providing the clinical trial materials and documentation required for Investigational New Drug (IND) applications.
About the project NextGen
Project NextGen is a $5 billion initiative to accelerate and streamline the rapid development of next-generation vaccines, medicines, and treatments through public-private collaboration. Project NextGen, led by NIAID and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of Strategic Preparedness and Response (ASPR), is a collaboration between the U.S. federal government and the private sector to advance a pipeline of innovative vaccines. This is a collaborative effort. , the purpose of which is to move drugs and therapeutics from the laboratory to clinical trials, into the private sector in later stages of development, and forward to U.S. Food and Drug Administration (FDA) clearance, approval, and commercial availability. .
About Emertex
Emergex is a clinical-stage, privately held biotechnology company headquartered in Abingdon, Oxon, UK, with an operating subsidiary in Doylestown, Pennsylvania, a microneedle manufacturing facility in Fremont, California, USA, and a GMP manufacturing vaccine facility in Milton Park, UK. I am. The company has created a drug designed to mimic the body’s natural T-cell immune response to destroy and eliminate pathogen-infected cells to protect against some of the world’s most pressing health threats. It has pioneered the development of 100% synthetic T-cell priming vaccine candidates. These candidates are also specifically designed for delivery using novel microneedles into the epidermal layer via skin immunization, with the aim of reducing the burden and logistics associated with traditional preventive measures. The initial indications that Emergex is aiming for are against infectious diseases: (i) viral infections such as betacoronaviruses, dengue fever, and pandemic influenza candidates, and (ii) cellular diseases such as tularemia caused by F. tularensis. Internal bacterial infection. Emergex is a growing, innovative immunotherapy candidate with the potential to provide rapid, broad-based (strain- and mutation-independent) and long-lasting prevention to reduce severe disease associated with infectious diseases. It has its own pipeline to continue.
For more information, please visit us online at www.emergexvaccines.com.
For the latest information, please visit our LinkedIn page or Twitter (X) account.
For more information, please contact us below.
